Vulvovaginal atrophy: New and upcoming approaches

Menopause

Volumn 16, Issue 1, 2009, Pages 5-7

  Simon, James A ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CONJUGATED ESTROGEN; ESTRADIOL; ESTRIOL; ESTROGEN; ESTRONE; PRASTERONE; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CLINICAL FEATURE; CLINICAL TRIAL; CYSTITIS; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG EFFECT; DRUG SAFETY; EDITORIAL; GAS CHROMATOGRAPHY; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; MASS SPECTROMETRY; PYELONEPHRITIS; VAGINA ATROPHY; ABSORPTION; ATROPHY; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; ESTROGEN THERAPY; FEMALE; INTRAVAGINAL DRUG ADMINISTRATION; MENOPAUSE; METABOLISM; PATHOLOGY; VAGINA; VULVA; WOMEN'S HEALTH;

ABSORPTION; ADMINISTRATION, INTRAVAGINAL; ATROPHY; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; VAGINA; VULVA; WOMEN'S HEALTH;

EID: 64049105055     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181924701     Document Type: Editorial

References (25)

1. Phil B, Fontanarosa PB, DeAngelis CD. The importance of the journal embargo. JAMA 2002;288:748-750.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
3. FDA. Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms - Recommendations for Clinical Evaluation. The Division of Drug Information (HFD-240), Center for Drug Evaluation and Research, 5600 Fishers Lane, Rockville, MD 20857. Available at: http://www.fda.gov/cder/guidance/index.htm. Accessed November 23, 2008.
4. Simon JA, Komi J. Postmenopausal Women's Attitudes: Vulvovaginal Atrophy and It's Symptoms. Dallas, TX: The North American Menopause Society (NAMS), Abstract no. LB-10. Menopause 2007;14:1107.
5. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;357-369.
6. Labrie F, Cusan L, Gomez J, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;16:30-36.
7. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17:584-587.
8. Simon JA, Reape KZ, Wininger S, Hait H. A randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. Fertil Steril 2008;90:1132-1138.
9. Simon JA, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1-8.
10. Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H. Twice-weekly synthetic conjugated estrogens vaginal cream compared to placebo for vaginal atrophy. Presented at: 56th Annual Clinical Meeting of the American College of Obstetricians and Gynecologist (ACOG); New Orleans, LA; May 4-7, 2008.
11. FDA news. Available at: www.fda.gov/bbs/topics/NEWS/2008/NEW01772.html. Updated: January 18, 2008. Posted: January 9, 2008. Accessed November 23, 2008.
12. Dessole S, Rubattu G, Ambrosini G, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 2004;11:49-56.
13. Foidart JM, Vervliet J, Buytaert P. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 1991;13:99-107.
14. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993;329:753-756.
15. Chollet JA, Carter G, Meyn LA, Mermelstein F, Balk JL. Efficacy and safety of vaginal estriol and progesterone in menopausal women with atrophic vaginitis. Menopause 2008. Submitted for publication.
16. Simon J, Komi J. Ospemifene, a new SERM, improves the symptoms of vaginal dryness and dyspareunia in postmenopausal women: results from a pivotal Phase 3 study. Presented at: 12th World Congress on the Menopause. International Menopause Society; Madrid, Spain; May 19-23, 2008.
17. Labrie F, Archer D, Bouchard C, et al. Intravaginal DHEA, the physiological and a highly efficient treatment of vaginal atrophy. Presented at: 19th Annual Meeting of The North American Menopause Society (NAMS). Is it menopause or is it aging? Orlando. Abstract no. LB-8. Menopause 2008;15:1230.
18. Labrie F, Matel C, Cusan L, et al. Comparison of serum estradiol levels following intravaginal estrogens and DHEA. Presented at: 19th Annual Meeting of The North American Menopause Society. Is it menopause or is it aging? Orlando. Abstract no. S-20. Menopause 2008;15:1208-1209.
19. Naessen T, Rodriguez-Macias K, Lithell H. Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. J Clin Endocrinol Metab 2001;86:2757-2762.
20. Naessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17b-estradiol. Am J Obstet Gynecol 1997;177:115-119.
21. Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. Am J Obstet Gynecol 2002;186:944-947.
22. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative Randomized Controlled Trial. JAMA 2004;291:1701-1712.
23. Lewis JS, Meeke K, Osipo C, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. JNCI 2005;97:1746-1759.
24. Lewis JS, Osipo C, Meeke K, Jordan VC. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Molec Biol 2005;94:131-141.
25. Trinkaus M, Chin S, Wolfman W, Simmons C. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008;13:222-231.